3.Where the health technology developer requests the joint scientific consultation to be carried out in parallel with the scientific advice, the timetable referred to in paragraph 1 shall be agreed between the HTA secretariat, in consultation with the JSC Subgroup, and the European Medicines Agency and shall be synchronised with the timing of the process for scientific advice as specified in Article 7(5), points (a) and (c), Article 9(2), point (a), Article 12(2) and Article 13(2), point (b).